USA flag logo/image

An Official Website of the United States Government

Multiple Indication Adjuvants

Award Information

Agency:
Department of Defense
Branch:
Office for Chemical and Biological Defense
Award ID:
86062
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
C081-105-0080
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOPROTECTION SYSTEMS CORP.
2901 S LOOP DR STE 3360 Ames, IA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Multiple Indication Adjuvants
Agency / Branch: DOD / CBD
Contract: W911NF-08-C-0044
Award Amount: $69,990.00
 

Abstract:

The objective of this study is to demonstrate the efficacy and broad applicability of the human immune-modulating alphaGal Adjuvant Technology for antiviral vaccine development. We will use viral vaccine candidates for the select Category A viral pathogens Zaire ebolavirus (ZEBOV, filovirus), Rift Valley fever virus (RVFV, bunyavirus), and Lassa virus (LV, arenavirus), to evaluate the adjuvant potency of the alphaGal Adjuvant Technology. This technology is based on the innate naturally acquired human immune response to galactose alpha(1,3)galactose alpha(1,4)N-acetylglucosamine (alphaGal) epitopes. In Phase I we will illustrate the broad application of the alphaGal Adjuvant Technology to antiviral vaccines by demonstrating that alphaGal-modification significantly enhances and modulates the immune response to select vaccines in a mouse model. In the Phase I Option, the optimized adjuvant conditions eliciting the best immune response to the different tested antiviral vaccines, based upon the mouse model immunological data, will be utilized in limited lethal challenge efficacy experiments to be conducted with wild-type virus under Biosafety Level (BSL)-4 conditions in the mouse model. Significant efficacy will lead to a Phase II proposal and further studies involving adjuvant efficacy in small rodents and non-human primates.

Principal Investigator:

Ramon Flick
Senior Director of Vaccine Developm
5152963944
rflick@bpsys.net

Business Contact:

Carl Langren
Chief Financial Officer
5153090138
clangren@bpsys.net
Small Business Information at Submission:

BIOPROTECTION SYSTEMS CORP.
2901 South Loop Drive Suite 3360 Ames, IA 50010

EIN/Tax ID: 202844633
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No